European phase 3/3b experience with long-acting cabotegravir and rilpivirine: efficacy, safety and virologic outcomes

被引：0
|
作者：
Molina, J. -M. [1 ]
Montes, M. L. [2 ]
Esser, S. [3 ]
De Castro, N. [1 ]
Patel, P. [4 ]
Dakhia, S. [5 ]
Polli, J. W. [4 ]
Garside, L. [6 ]
D'Amico, R. [4 ]
Talarico, C. [4 ]
Van Eygen, V. [7 ]
Vandermeulen, K. [7 ]
Spreen, W. R. [4 ]
Aboud, M. [5 ]
Bosse, M. [8 ]
机构：
[1] Univ Paris Diderot, St Louis Hosp, Infect Dis, Paris, France
[2] La Paz Univ Hosp, HIV Unit, Madrid, Spain
[3] Univ Hosp Duisburg Essen, Essen, Germany
[4] ViiV Healthcare, Res Triangle Pk, NC USA
[5] ViiV Healthcare, Brentford, England
[6] GlaxoSmithKline, London, England
[7] Janssen Res & Dev, Beerse, Belgium
[8] ViiV Healthcare, San Diego, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/67
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [31] Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials
    Patel, Parul
    Ford, Susan L.
    Baker, Mark
    Meyer, Claudia
    Garside, Louise
    D'Amico, Ronald
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Polli, Joseph W.
    Seal, Ciara
    Yaguee Munoz, Itziar
    Thiagarajah, Shanker
    Birmingham, Eileen
    Spreen, William R.
    Baugh, Bryan
    van Wyk, Jean
    Vannappagari, Vani
    HIV MEDICINE, 2023, 24 (05) : 568 - 579
  • [32] Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
    Wu, Yuan-ni
    Yu, Hai
    Lu, Lianfeng
    Li, Xiaodi
    Liu, Xiaosheng
    Cao, Wei
    Li, Taisheng
    BMJ OPEN, 2022, 12 (12):
  • [33] Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
    Fonner, Virginia A.
    Ridgeway, Kathleen
    van der Straten, Ariane
    Lorenzetti, Lara
    Dinh, Nhi
    Rodolph, Michelle
    Schaefer, Robin
    Schmidt, Heather-Marie A.
    Nguyen, Van Thi Thuy
    Radebe, Mopo
    Peralta, Hortencia
    Baggaley, Rachel
    AIDS, 2023, 37 (06) : 957 - 966
  • [34] Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: Efficacy and tolerance during the first 72 weeks
    Psomas, C. K.
    Halfon, P.
    Salnikova, M.
    Khiri, H.
    Tichadelle, F.
    Allemand, J.
    Neant, N.
    Solas, C.
    Philibert, P.
    HIV MEDICINE, 2023, 24 : 81 - 82
  • [35] Efficacy and safety of long-acting cabotegravir plus rilpivirine at All Saints Clinic in Wroclaw (Poland): real-life single-centre 2-year experience
    Dawiec, Marzena
    Gasiorowski, Jacek
    Szymczak, Aleksandra
    Zinczuk, Aleksander
    Inglot, Malgorzata
    Knysz, Brygida
    Zielinska, Kamila
    Bortkiewicz, Joanna
    Furdal, Michal
    Bozejko, Mateusz
    Szetela, Bartosz
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 109 - 109
  • [36] Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
    Murray, Miranda
    Antela, Antonio
    Mills, Anthony
    Huang, Jenny
    Jaeger, Hans
    Bernal, Enrique
    Lombaard, Johan
    Katner, Harold
    Walmsley, Sharon
    Khuong-Josses, Marie-Aude
    Hudson, Krischan
    Dorey, David
    Griffith, Sandy
    Spreen, William
    Vanveggel, Simon
    Shaefer, Mark
    Margolis, David
    Chounta, Vasiliki
    AIDS AND BEHAVIOR, 2020, 24 (12) : 3533 - 3544
  • [37] Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
    Miranda Murray
    Antonio Antela
    Anthony Mills
    Jenny Huang
    Hans Jäger
    Enrique Bernal
    Johan Lombaard
    Harold Katner
    Sharon Walmsley
    Marie-Aude Khuong-Josses
    Krischan Hudson
    David Dorey
    Sandy Griffith
    William Spreen
    Simon Vanveggel
    Mark Shaefer
    David Margolis
    Vasiliki Chounta
    AIDS and Behavior, 2020, 24 : 3533 - 3544
  • [38] Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results (Sept, dkae308, 2024)
    Serris, Alexandra
    Ferre, Valentine Marie
    Le Hingrat, Quentin
    Bachelard, Antoine
    Charpentier, Charlotte
    Exarchopoulos, Marina
    Damond, Florence
    Phung, Bao-Chau
    Landman, Roland
    Yazdanpanah, Yazdan
    Descamps, Diane
    Joly, Veronique
    Peytavin, Gilles
    Ghosn, Jade
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (12) : 3370 - 3370
  • [39] Central nervous system safety of long-acting cabotegravir/rilpivirine in patients with previous oral INSTI-related CNS toxicity
    Moreno, Ana
    Del Campo, Santos
    Jesus Vivancos, Maria
    Velez, Manuel
    Luis Casado, Jose
    Martinez, Javier
    Dronda, Fernando
    Moreno, Santiago
    Jesus Perez-Elias, Maria
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 84 - 85
  • [40] Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
    Chounta, V.
    Wu, S.
    Upadhyay, O.
    Griffith, S.
    Harrington, C.
    Orkin, C.
    Swindells, S.
    Spreen, W.
    Margolis, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 24 - 24
12345